---
title: "4D Molecular Therapeutics Chief Legal Officer Scott Bizily disposes of 6,566 common shares valued at $91,924"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291584229.md"
description: "Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, disposed of 6,566 common shares valued at $91,924. The transaction involved exercising options for 6,566 shares at prices between $4.14 and $6.49 per share, followed by selling all acquired shares at $14 each. This sale reduced his direct holdings to 8,617 shares. The information was published via EDGAR on July 2, 2026."
datetime: "2026-07-02T20:08:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291584229.md)
  - [en](https://longbridge.com/en/news/291584229.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291584229.md)
---

# 4D Molecular Therapeutics Chief Legal Officer Scott Bizily disposes of 6,566 common shares valued at $91,924

-   4D Molecular Therapeutics Chief Legal Officer Scott Bizily acquired 6,566 common shares on June 30, 2026. \* Purchase reflected option exercises totaling 6,566 shares at USD 4.14 and USD 6.49 per share. \* Bizily sold 6,566 shares at USD 14, cutting direct holdings to 8,617 shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001920738-26-000004), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [FDMT.US](https://longbridge.com/en/quote/FDMT.US.md)

## Related News & Research

- [4D Molecular Therapeutics CEO David Kirn sells USD 739,829 in common shares](https://longbridge.com/en/news/292676162.md)
- [4D Molecular Therapeutics CEO David Kirn disposes of 114,746 common shares worth $1.2 million](https://longbridge.com/en/news/290604616.md)
- [Salzgitter sells Klöckner DESMA to NAME & MAWI Partners](https://longbridge.com/en/news/294659332.md)
- [Estrela swaps auditor to BKR Lopes Machado from Tríade starting 2026 financial year](https://longbridge.com/en/news/294557755.md)
- [TOU: Strong Q2 cash flow, LPG export growth, and disciplined capital drive robust 2026–2028 outlook](https://longbridge.com/en/news/294266970.md)